{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:19:23Z","timestamp":1760573963769,"version":"build-2065373602"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>There is an unmet need for therapeutics with a novel mechanism to address Q9 symptoms associated with conditions where aberrant glutamatergic neurotransmission is presumed pathogenic. One enzyme of potential relevance is glutamate carboxypeptidase II (GCPII), a brain metallopeptidase with significantly upregulated activity in nervous tissues following neurodegeneration or injury. Current inhibitors are too polar and charged leading to minimal brain penetration necessitating high systemic doses or direct brain injection. Our efforts are focused on identifying new inhibitor scaffolds with favorable brain penetration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein, we used a newly developed dual-stream liquid chromatography mass spectrometry (LC\/MS\/MS) substrate cleavage assay to screen two small molecule libraries. The two top confirmed hits were cefsulodin (IC<jats:sub>50<\/jats:sub> = 2 \u00b1 0.1 \u03bcM) and amaranth (IC<jats:sub>50<\/jats:sub> = 0.3 \u00b1 0.01 \u03bcM). The interactions of Amaranth and cefsulodin with GCPII were characterized with mode of inhibition (MOI) studies, nano differential scanning fluorimetry (DSF) thermal shift assay, and binding site was modeled with in-silico docking. As cefsulodin is an antibiotic used clinically to treat bacterial meningitis, we tested the compound\u2019s brain pharmacokinetics (PK) in mice using a sensitive LC\/MS method we developed. Moreover, following confirmation and characterization of cefsulodin and amaranth as viable hits an SAR investigation was conducted with analogs of both compounds.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A first derivative analysis of the DSF data revealed a shift in melting temperature of \u0394 0.76 \u00b0C (\u00b10.04) for amaranth at 25 \u03bcM and 80.41 \u00b0C (\u00b10.05) for cefsulodin at 250 \u03bcM, suggesting both compounds are acting as stabilizers for the enzyme. Increasing concentrations of cefsulodin increased the Km of N-acetyl-aspartyl-glutamate (NAAG) as a substrate with no change in Vmax, suggesting active site competitive inhibition. In contrast, increasing concentrations of amaranth led to reductions in Vmax while the Km remained constant, suggesting a non-competitive MOI. Results from in-silico docking studies complemented this MOI data, suggesting cefsulodin likely binds in the active site while amaranth likely binds in an allosteric site. Our PK study demonstrated that administration of cefsulodin (100 mg\/kg IP) led to a Cmax of 4 \u03bcM in the brain, exceeding its GCPII IC<jats:sub>50<\/jats:sub> value.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our new screening approaches identified novel inhibitors of GCPII that could serve as molecular templates for further structural optimization.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1646207","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:41:52Z","timestamp":1760506912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mass spectrometry-guided discovery of novel GCPII inhibitor scaffolds"],"prefix":"10.3389","volume":"16","author":[{"given":"Robyn","family":"Wiseman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Janiszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nate","family":"Hoxie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chae Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ronzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan H.","family":"Shrimp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davina","family":"Adderley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesha","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Rais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Alt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Kales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara S.","family":"Slusher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"758212","DOI":"10.1155\/2014\/758212","article-title":"Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison","volume":"2014","author":"Adams","year":"2014","journal-title":"Schizophr. Res. Treat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1744-8069-6","DOI":"10.1186\/1744-8069-6-60","article-title":"Endogenous N-Acetylaspartylglutamate (NAAG) inhibits synaptic Plasticity\/Transmission in the amygdala in a mouse inflammatory pain model","volume":"6","author":"Adedoyin","year":"2010","journal-title":"Mol. Pain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coph.2014.11.001","article-title":"Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease","volume":"20","author":"Amalric","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1176\/appi.ajp.2020.20101458","article-title":"The evolutionary expansion of mGluR3-NAAG-GCPII signaling: relevance to human intelligence and cognitive disorders","volume":"177","author":"Amy","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"105201","DOI":"10.1016\/j.nbd.2020.105201","article-title":"Neuroprotective effects of a dendrimer-based glutamate carboxypeptidase inhibitor on superoxide dismutase transgenic mice after neonatal hypoxic-ischemic brain injury","volume":"148","author":"Arteaga Cabeza","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1471-4159.2005.03361.x","article-title":"Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury","volume":"95","author":"Bacich","year":"2005","journal-title":"J. Neurochem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.0022-3042.2001.00715.x","article-title":"Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II","volume":"80","author":"Barinka","year":"2002","journal-title":"J. Neurochem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e12431","DOI":"10.1002\/trc2.12431","article-title":"Chronic GCPII (glutamate-carboxypeptidase-II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques","volume":"9","author":"Bathla","year":"2023","journal-title":"Alzheimers Dement. (N Y)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/j.1471-4159.1984.tb05396.x","article-title":"Elevation of the extracellular concentrations of glutamate and aspartate in Rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis","volume":"43","author":"Benveniste","year":"1984","journal-title":"J. Neurochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12640-009-9114-1","article-title":"Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat","volume":"17","author":"Carozzi","year":"2010","journal-title":"Neurotox. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.npep.2003.08.001","article-title":"Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat","volume":"37","author":"Carpenter","year":"2003","journal-title":"Neuropeptides"},{"key":"B12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1124\/jpet.300.2.662","article-title":"Effect of 2-(Phosphono-methyl)-pentanedioic acid on Allodynia and afferent ectopic discharges in a rat model of neuropathic pain","volume":"300","author":"Chen","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.pbb.2011.06.023","article-title":"Glutamate mediated signaling in the pathophysiology of autism spectrum disorders","volume":"100","author":"Choudhury","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B14","doi-asserted-by":"publisher","first-page":"760270","DOI":"10.3389\/fnagi.2021.760270","article-title":"Glutamate carboxypeptidase II in aging rat prefrontal cortex impairs working memory performance","volume":"13","author":"Datta","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1111\/bph.13919","article-title":"Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research","volume":"174","author":"Dauvermann","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12604","DOI":"10.1073\/pnas.0405077101","article-title":"Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia","volume":"101","author":"Egan","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.brainres.2011.04.022","article-title":"Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI","volume":"1395","author":"Feng","year":"2011","journal-title":"Brain Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.brainres.2012.06.021","article-title":"NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia","volume":"1469","author":"Feng","year":"2012","journal-title":"Brain Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1759091419855541","DOI":"10.1177\/1759091419855541","article-title":"Amyloid beta-related alterations to glutamate signaling dynamics during Alzheimer's Disease progression","volume":"11","author":"Findley","year":"2019","journal-title":"ASN Neuro"},{"key":"B20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/jnc.13123","article-title":"Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury","volume":"134","author":"Gao","year":"2015","journal-title":"J. Neurochem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"114786","DOI":"10.1016\/j.bcp.2021.114786","article-title":"Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: opportunities for novel therapeutics development","volume":"193","author":"Green","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainres.2013.03.043","article-title":"NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia","volume":"1515","author":"Gurkoff","year":"2013","journal-title":"Brain Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s0304-3940(00)01444-0","article-title":"N-acetylated-\u03b1-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia","volume":"292","author":"Harada","year":"2000","journal-title":"Neurosci. Lett."},{"key":"B24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/0269881108089818","article-title":"The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia","volume":"22","author":"Harrison","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.brainres.2016.01.035","article-title":"Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis","volume":"1635","author":"Hollinger","year":"2016","journal-title":"Brain Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7150\/ntno.63158","article-title":"Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis","volume":"6","author":"Hollinger","year":"2022","journal-title":"Nanotheranostics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9772","article-title":"Development of a high-throughput dual-stream liquid chromatography-tandem mass spectrometry method to screen for inhibitors of glutamate carboxypeptidase II","author":"Hoxie","year":"2024","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1021\/jm0001774","article-title":"Design and pharmacological activity of phosphinic acid based NAALADase inhibitors","volume":"44","author":"Jackson","year":"2001","journal-title":"J. Med. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2012.11.027","article-title":"NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test","volume":"701","author":"Janczura","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"107913","DOI":"10.1016\/j.isci.2023.107913","article-title":"mNSCs overexpressing Rimkla transplantation facilitates cognitive recovery in a mouse model of traumatic brain injury","volume":"26","author":"Ji","year":"2023","journal-title":"iScience"},{"key":"B31","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/cercor\/bhx005","article-title":"mGluR2 versus mGluR3 metabotropic glutamate receptors in primate dorsolateral prefrontal cortex: postsynaptic mGluR3 strengthen working memory networks","volume":"28","author":"Jin","year":"2017","journal-title":"Cereb. Cortex"},{"key":"B32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00213-005-0182-5","article-title":"2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57\/Bl mice","volume":"183","author":"Kozela","year":"2005","journal-title":"Psychopharmacology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/jm0306226","article-title":"Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents","volume":"47","author":"Kozikowski","year":"2004","journal-title":"J. Med. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s0378-4347(00)80438-7","article-title":"Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography","volume":"228","author":"Lecaillon","year":"1982","journal-title":"J. Chromatogr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2004.12.008","article-title":"Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats","volume":"508","author":"Long","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1021\/jm020515w","article-title":"Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor","volume":"46","author":"Majer","year":"2003","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3389\/fnmol.2018.00383","article-title":"Group II metabotropic glutamate receptors: role in pain mechanisms and pain modulation","volume":"11","author":"Mazzitelli","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000238441","article-title":"Cefsulodin penetration into rat brain: extracellular versus total concentration","volume":"32","author":"Meulemans","year":"1986","journal-title":"Chemotherapy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000238676","article-title":"Pharmacokinetics of cefsulodin in rat cerebrospinal fluid during experimental Pseudomonas aeruginosa Meningitis","volume":"35","author":"Meulemans","year":"2009","journal-title":"Chemotherapy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/nrn3200","article-title":"The ageing cortical synapse: hallmarks and implications for cognitive decline","volume":"13","author":"Morrison","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1111\/febs.12857","article-title":"Structural and biochemical characterization of the folyl-poly-\u03b3-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II","volume":"281","author":"Navr\u00e1til","year":"2014","journal-title":"Febs J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1744806917697008","DOI":"10.1177\/1744806917697008","article-title":"A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA","volume":"13","author":"Nonaka","year":"2017","journal-title":"Mol. Pain"},{"key":"B44","first-page":"857","article-title":"Excitotoxic mechanisms of epileptic brain damage","volume":"44","author":"Olney","year":"1986","journal-title":"Adv. neurology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1038\/tp.2012.68","article-title":"NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia","volume":"2","author":"Olszewski","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1007\/s11064-017-2181-4","article-title":"NAAG Peptidase Inhibitors Act via mGluR3: animal models of memory, alzheimer\u2019s, and ethanol intoxication","volume":"42","author":"Olszewski","year":"2017","journal-title":"Neurochem. Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s10068-023-01405-y","article-title":"Simultaneous detection of residues of 34 beta-lactam antibiotics in livestock and fish samples through liquid chromatography-tandem mass spectrometry","volume":"33","author":"Park","year":"2024","journal-title":"Food Sci. Biotechnol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejphar.2009.10.062","article-title":"Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats","volume":"627","author":"Peng","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1007\/s12035-019-01854-9","article-title":"Cellular and molecular changes in hippocampal glutamate signaling and alterations in learning, attention, and impulsivity following prenatal nicotine exposure","volume":"57","author":"Polli","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.npp.1300048","article-title":"Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA","volume":"28","author":"Popik","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"20101","DOI":"10.1073\/pnas.1209934109","article-title":"Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis","volume":"109","author":"Rahn","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/s0003-2697(02)00286-5","article-title":"Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay","volume":"310","author":"Rojas","year":"2002","journal-title":"Anal. Biochem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/ana.410190202","article-title":"Glutamate and the pathophysiology of hypoxic\u2013ischemic brain damage","volume":"19","author":"Rothman","year":"1986","journal-title":"Ann. Neurology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000530389","article-title":"Dendrimer-Conjugated glutamate carboxypeptidase II inhibitor restores microglial changes in a rabbit model of cerebral Palsy","volume":"45","author":"Sah","year":"2023","journal-title":"Dev. Neurosci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1196","DOI":"10.1038\/tp.2017.172","article-title":"Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk","volume":"7","author":"Saini","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/sj.npp.1301669","article-title":"Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP","volume":"33","author":"Sartorius","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/1098-2396(200011)38:2<161::AID-SYN7>3.0.CO;2-G","article-title":"Modulation of behavioral sensitization to cocaine by NAALADase inhibition","volume":"38","author":"Shippenberg","year":"2000","journal-title":"Synapse"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/70971","article-title":"Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury","volume":"5","author":"Slusher","year":"1999","journal-title":"Nat. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.brainres.2010.11.048","article-title":"Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice","volume":"1371","author":"Takatsu","year":"2011","journal-title":"Brain Res."},{"key":"B61","first-page":"464","article-title":"2-MPPA, a selective inhibitor of GCPII (NAALADase\/PSMA), attenuates chemotherapy-induced neuropathy in mice","volume":"66","author":"Tang","year":"2006","journal-title":"Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"593","DOI":"10.7164\/antibiotics.31.593","article-title":"Absorption, distribution and excretion of cefsulodin, an antipseudomonal cephalosporin, in mice, rats and dogs","volume":"31","author":"Tsuchiya","year":"1978","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1124\/jpet.113.205039","article-title":"Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism","volume":"346","author":"Vornov","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.apha.2016.01.007","article-title":"Still naag'ing after all these years: the continuing pursuit of GCPII inhibitors","volume":"76","author":"Vornov","year":"2016","journal-title":"Adv. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s11064-019-02909-y","article-title":"Looking for drugs in all the wrong places: use of GCPII inhibitors outside the brain","volume":"45","author":"Vornov","year":"2020","journal-title":"Neurochem. Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/s0022-3565(24)29300-9","article-title":"Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats","volume":"299","author":"Williams","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B67","article-title":"Chapter Two - Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function","volume-title":"Advances in pharmacology","author":"Wiseman","year":"2025"},{"key":"B68","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/s0028-3908(02)00124-7","article-title":"NAALADase (GCP II) inhibition prevents cocaine-kindled seizures","volume":"43","author":"Witkin","year":"2002","journal-title":"Neuropharmacology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1124\/jpet.112.197665","article-title":"The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy","volume":"343","author":"Wozniak","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.neuropharm.2009.06.016","article-title":"N-acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats","volume":"58","author":"XI","year":"","journal-title":"Neuropharmacology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1471-4159.2009.06478.x","article-title":"Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2\/3-mediated mechanism","volume":"112","author":"XI","year":"","journal-title":"J. Neurochem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1744-8069-8","DOI":"10.1186\/1744-8069-8-67","article-title":"NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation","volume":"8","author":"Yamada","year":"2012","journal-title":"Mol. Pain"},{"key":"B73","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/s0006-8993(01)02650-6","article-title":"Spinal N-acetyl-\u03b1-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat","volume":"909","author":"Yamamoto","year":"","journal-title":"Brain Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/s0306-4522(00)00502-9","article-title":"Inhibition of spinal N-acetylated-\u03b1-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test","volume":"102","author":"Yamamoto","year":"","journal-title":"Neuroscience"},{"key":"B75","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1460-9568.2004.03504.x","article-title":"Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model","volume":"20","author":"Yamamoto","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1460-9568.2006.05272.x","article-title":"Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats","volume":"25","author":"Yamamoto","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1744-8069-4","DOI":"10.1186\/1744-8069-4-31","article-title":"Intracerebroventricular administration of N-Acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain","volume":"4","author":"Yamamoto","year":"2008","journal-title":"Mol. Pain"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1038\/s41380-022-01656-x","article-title":"Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: potential therapeutic target for neuroinflammatory cognitive disorders","volume":"27","author":"Yang","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1529-8027.2002.02026_24.x","article-title":"GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB\/WOR rats","volume":"7","author":"Zhang","year":"2002","journal-title":"J. Peripher. Nerv. Syst."},{"key":"B80","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jns.2006.05.052","article-title":"The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy","volume":"247","author":"Zhang","year":"2006","journal-title":"J. Neurological Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2023.04.017","article-title":"Dendrimer-enabled targeted delivery attenuates glutamate excitotoxicity and improves motor function in a rabbit model of cerebral palsy","volume":"358","author":"Zhang","year":"2023","journal-title":"J. Control. Release"},{"key":"B82","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1089\/neu.2005.22.266","article-title":"NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats","volume":"22","author":"Zhong","year":"2005","journal-title":"J. Neurotrauma"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1471-4159.2006.03786.x","article-title":"NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat","volume":"97","author":"Zhong","year":"2006","journal-title":"J. Neurochem."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e01399-23","DOI":"10.1128\/aac.01399-23","article-title":"Comprehensive stability analysis of 13 beta-lactams and beta-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation","volume":"68","author":"Zhou","year":"2024","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:41:54Z","timestamp":1760506914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":84,"alternative-id":["10.3389\/fphar.2025.1646207"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1646207","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"1646207"}}